Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Licenses Kreutzer-Limmer RNAi Patents to Bioneer

NEW YORK, May 24 (GenomeWeb News) - Alnylam Pharmaceuticals will license its RNAi research products to Bioneer, the company said today.

 

The non-exclusive license is for products under the Kreutzer-Limmer patent family, which covers small interfering RNAs and their use to mediate RNAi in mammalian cells. Alnylam is the exclusive owner of these patents.

 

Financial details were not disclosed.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.